Print Page     Close Window     

SEC Filings

SERES THERAPEUTICS, INC. filed this Form 8-K on 06/12/2017
Entire Document

Slide 14

SER-109 Phase 2 study post read-out analyses and findings SER-109 analyses Key issues addressed Clinical Detailed analyses of clinical data Investigation of C. difficile diagnostics Pharmacodynamics / microbiome analyses Investigation of drug activity Chemistry, Manufacturing and Controls (CMC) Drug product distribution and handling Phase 1b to Phase 2 manufacturing and formulation changes, and potential impact on drug activity Diagnosis - Misdiagnoses may have occurred both in some patients entering the trial, as well as for recurrences diagnosed during the study Key Findings: Factors contributing to SER-109 Phase 2 study result Dose - The dose used in the Phase 2 study may have been suboptimal in certain patients See January 31, 2017 press release for additional information

© Seres Therapeutics. All Rights Reserved.